Strontium fructose Osteoporosis

Strontium fructose may be a new effective treatment for postmenopausal Osteoporosis. Ever since the discovery that strontium increases the density of bones (1910) there has been an ongoing study of this mineral by researchers concerned with Osteoporosis and Osteopenia.

Background:

We know that there have been some serious cardiac side effects of thepharmaceutical form strontium ranelate. We also know the a pharmaceutical company in the United States has been working on another form: strontium malonate.

But the journal Acta Pharmacologica Sinica published a study in 2012 by Chinese researchers showing the "protective effects of strontium fructose 1,6-diphosphate (FDP-Sr), a novel strontium salt that combined fructose 1,6-diphosphate (FDP) with strontium".

This is to me, exciting news.

Strontium fructose study

The study was done on eighty female Sprague-Dawley rats. Some were ovariectomized (OVX); others had sham operations.

But what isreally encouraging is that the researchers concluded: "FDP-Sr may be an effective treatment for postmenopausal osteoporosis." (The link for the full study is above.)

Another study was published in 2013 by the European Journal Pharmacology " Metabonomic profiling in studying anti-osteoporosis effects of strontium fructose 1,6-diphosphate on estrogen deficiency-induced osteoporosis in rats by GC/TOF-MS." Again the study was done by Chinese scientists.

The abstract of this study stated:

"A novel strontium salt compound strontium fructose 1, 6-diphosphate (FDP-Sr) has been proved to have highly effective for bone loss via dual effects of stimulating bone formation and suppressing bone absorption. In the present study, metabolomic approach was used to identify and study potential biomarkers associated with the effect and safety of FDP-Sr. . . .

Some metabolites including homocysteine, arachidonic acid, alanine, and hydroxyproline, which significantly changed during osteoporosis progression could be effectively reversed after FDP-Sr therapy. Of course some metabolites such as uric acid, glyceric acid, octadecadienoic acid, docosahexaenoic acid, oleic acid, and hexadecanoic acid were not found to reverse significantly after FDP-Sr administration.

These results delineated the FDP-Sr effects-related metabolic alterations in the bone loss rats, suggesting that metabonomic analysis could provide helpful information on the new potential biomarkers relating to the mechanism of anti-osteoporosis action and side effects of FDP-Sr against estrogen deficiency induced bone loss." (The underlining indicates encouraging conclusion about this potential new drug.)

If and when it comes to market, I shall update this page. Meantime you might want to mention it to your health care provider so s/he can be on the lookout for any new developments in your own country.